The femtech company MiMARK Diagnostics raises €4.2M in seed round
MiMARK Diagnostics, a spinoff from the Vall d’Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage to impact on gynecological diagnostics. The femtech company is one of the eleven companies participating in the BCN Health Booster accelerator, led by the Barcelona Science Park, Barcelona City Council, Barcelona Activa and Biocat.
The substantial investment will drive the development of the company’s groundbreaking gynecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Council) and private investors, including Clave Capital, Nara Capital, Namarel Ventures, and WA4STEAM investing in May this year, and CDTI Innvierte, Inveready and Canterbury Scientific, joining later on.
According to Marina Rigau, company’s CEO and co-founder: “This seed funding represents a significant milestone for MiMARK and validates our commitment to improve gynecological diagnostics. Thanks to this funding we will advance on bringing our first product to the market; an In Vitro Diagnostic for Endometrial Cancer. We are excited about the journey ahead and the positive impact our innovations will have on women’s health.”
MiMARK Diagnostics has achieved noteworthy milestones in the development of its flagship product, WomEC, an in vitro diagnostic test for endometrial cancer. This medical device is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.
In addition to accelerating the development of its diagnostic test, MiMARK Diagnostics future projects also include strengthening the company’s capabilities to initiate new research projects and strengthen collaborations with leading institutions, health professionals and industry partners to address other unmet clinical needs in gynecological health, such as improving the diagnosis of endometriosis. The primary purpose is to take advantage of gynecological fluids as a source of biomarkers.